An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma
Mark Agulnik, Brian Schulte, Steven I. Robinson, Angela C. Hirbe, Kevin R. Kozak, Sant P. Chawla, Steven Attia, Alfred Rademaker, Hui Zhang, Susan Abbinanti, Rasima Cehic, Varun Monga, Mohammed Milhem, Scott H. Okuno, Brian A. Van Tine
Topics & Concepts
RegorafenibMedicineAdverse effectClinical endpointAngiosarcomaInternal medicinePhases of clinical researchSurgeryOncologyRefractory (planetary science)Response Evaluation Criteria in Solid TumorsClinical trialCancerColorectal cancerPhysicsAstrobiologyVascular Tumors and AngiosarcomasCardiac tumors and thrombiSoft tissue tumors and treatment